AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Denali Therapeutics Inc. Director's Dealing 2021

May 5, 2021

31637_dirs_2021-05-05_00711e6c-4621-487f-90b1-e02c99979822.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-05-03

Reporting Person: Tessier-Lavigne Marc (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-03	Common Stock	S	3139	$60.08	Disposed	2589157	Direct
2021-05-03	Common Stock	S	98	$61.20	Disposed	2589059	Direct

Footnotes

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: Includes 3,253 restricted stock units.